Beijing InnoCare Pharma Tech
CompanyChina
Beijing InnoCare Pharma Tech develops one asset, in phase 3 (orelabrutinib in diffuse large B-cell lymphoma). Mostly small molecule acting on BTK; based in China.
- 1
- Asset
- Furthest stage
- Phase 3
- 15
- Trials
- 5
- Signals
Pipeline
1Inhibits Bruton's tyrosine kinase, blocking B-cell receptor signaling and malignant B-cell survival.
Phase 3, Small molecule, BTK, diffuse large B-cell lymphoma, mantle cell lymphoma
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials16
- Signals9
- Similar companies6